Cost-effectiveness of Evolocumab in Adult patients with atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective
W Xie, Y Song, X Qin, P Jin - Advances in Therapy, 2023 - Springer
Introduction To assess the cost-effectiveness of evolocumab with statins versus placebo
combined with statins in the treatment of adult patients with atherosclerotic cardiovascular …
combined with statins in the treatment of adult patients with atherosclerotic cardiovascular …
Cost-effectiveness of evolocumab therapy for myocardial infarction: the Chinese healthcare perspective
Z Liang, Q Chen, F Yang, X Yan, X Zhang… - … drugs and therapy, 2021 - Springer
Purpose Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an
indispensable lipid-lowering treatment option, but their cost-effectiveness has been …
indispensable lipid-lowering treatment option, but their cost-effectiveness has been …
Cost-effectiveness analysis of evolocumab in adult patients with atherosclerotic cardiovascular disease in Canada
J Grégoire, S Champsi, M Jobin, L Martinez… - Advances in …, 2022 - Springer
Introduction To evaluate the cost-effectiveness of evolocumab when added to standard of
care lipid-lowering treatment (LLT) for patients with atherosclerotic cardiovascular disease …
care lipid-lowering treatment (LLT) for patients with atherosclerotic cardiovascular disease …
Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study
M Chai, H Zhang, L Yang, J Liang, H Han… - Chinese Medical …, 2023 - mednexus.org
Low-density lipoprotein cholesterol (LDL-C) is an independent risk factor for atherosclerotic
cardiovascular disease (ASCVD). Even after lipid-lowering therapy (LLT) with statins or …
cardiovascular disease (ASCVD). Even after lipid-lowering therapy (LLT) with statins or …
Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 …
H Tan, W Li, Z Huang, Y Han, X Huang, D Li… - Cardiology and …, 2023 - Springer
Introduction Evolocumab, a fully human proprotein convertase/subtilisin kexin type 9
inhibitor antibody, significantly lowers low-density lipoprotein cholesterol (LDL-C) in patients …
inhibitor antibody, significantly lowers low-density lipoprotein cholesterol (LDL-C) in patients …
[HTML][HTML] A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk
A Kiyosue, N Honarpour, C Kurtz, A Xue… - The American journal of …, 2016 - Elsevier
Evolocumab (AMG 145), a fully human monoclonal antibody against PCSK9, significantly
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
Effects of evolocumab (AMG 145) in hypercholesterolemic, statin-treated, Japanese patients at high cardiovascular risk: Results from the phase III yukawa 2 study
A Kiyosue, N Honarpour, A Xue, S Wasserman… - Journal of the American …, 2015 - jacc.org
Background: Evolocumab (AMG 145), a fully human monoclonal antibody inhibiting PCSK9,
significantly reduced LDL-C in phase 2 and 3 studies. This phase 3 study (the largest …
significantly reduced LDL-C in phase 2 and 3 studies. This phase 3 study (the largest …
Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease
GC Fonarow, B van Hout, G Villa, J Arellano… - JAMA …, 2019 - jamanetwork.com
Importance In October 2018, evolocumab was made available at a reduced annual list price
of $5850 in the United States. This 60% reduction was aimed at improving patient access by …
of $5850 in the United States. This 60% reduction was aimed at improving patient access by …
Evolocumab is initiated in Central and Eastern Europe at much higher LDL-C levels than recommended in guidelines: Results from the observational HEYMANS study
V Blaha, R Margoczy, I Petrov… - Journal of …, 2023 - journals.sagepub.com
Purpose: We examined clinical characteristics and low-density lipoprotein cholesterol (LDL-
C) lowering in patients initiating evolocumab in real-world practice in a Central and Eastern …
C) lowering in patients initiating evolocumab in real-world practice in a Central and Eastern …
Comparison of Evolocumab and Ezetimibe, both combined with Statin Therapy, for patients with recent Acute Coronary Syndrome: a cost-effectiveness analysis from …
X Xi, X Wang, W Xie, Y Jia, SZ Sanchez… - … Drugs and Therapy, 2023 - Springer
Purpose To assess the cost-effectiveness of evolocumab, a PCSK9 (proprotein convertase
subtilisin/kexin type 9) inhibitor, compared with ezetimibe, both added to background statin …
subtilisin/kexin type 9) inhibitor, compared with ezetimibe, both added to background statin …
相关搜索
- cost effectiveness evolocumab in patients
- cost effectiveness healthcare perspective
- chinese patients safety of evolocumab
- healthcare perspective evolocumab therapy
- japanese patients effects of evolocumab
- chinese patients cardiovascular risk
- cost effectiveness myocardial infarction
- chinese patients hua tuo
- healthcare perspective myocardial infarction
- chinese patients mixed dyslipidemia
- chinese patients primary hypercholesterolemia
- safety of evolocumab cardiovascular risk
- cost effectiveness evolocumab therapy
- chinese patients effects and safety
- effects and safety cardiovascular risk
- chinese patients efficacy and safety